These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37418629)

  • 1. Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
    Liu M; Zhang D; Wang D; Wu X; Zhang Y; Yin J; Zhu G
    J Infect Dis; 2023 Nov; 228(10):1430-1440. PubMed ID: 37418629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.
    Guo F; Zhang H; McNair NN; Mead JR; Zhu G
    J Infect Dis; 2018 Mar; 217(7):1110-1117. PubMed ID: 29300993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
    Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
    Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
    Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
    Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.
    Li X; Brasseur P; Agnamey P; Leméteil D; Favennec L; Ballet JJ; Rossignol JF
    Folia Parasitol (Praha); 2003 Mar; 50(1):19-22. PubMed ID: 12735719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
    Ndao M; Nath-Chowdhury M; Sajid M; Marcus V; Mashiyama ST; Sakanari J; Chow E; Mackey Z; Land KM; Jacobson MP; Kalyanaraman C; McKerrow JH; Arrowood MJ; Caffrey CR
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6063-73. PubMed ID: 24060869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of particulate drug formulation against C. parvum: Formulation, characterization and in vivo efficacy.
    Blanco-García E; Guerrero-Callejas F; Blanco-Méndez J; Gómez-Couso H; Luzardo-Álvarez A
    Eur J Pharm Sci; 2016 Sep; 92():74-85. PubMed ID: 27381880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model.
    Perrucci S; Fichi G; Buggiani C; Rossi G; Flamini G
    Parasitol Res; 2006 Jul; 99(2):184-8. PubMed ID: 16547730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin: A promising treatment for Cryptosporidium parvum infection in immunosuppressed BALB/c mice.
    Asadpour M; Namazi F; Razavi SM; Nazifi S
    Exp Parasitol; 2018 Dec; 195():59-65. PubMed ID: 30385266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
    Baishanbo A; Gargala G; Duclos C; François A; Rossignol JF; Ballet JJ; Favennec L
    J Antimicrob Chemother; 2006 Feb; 57(2):353-5. PubMed ID: 16361328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis.
    Giacometti A; Burzacchini F; Cirioni O; Barchiesi F; Dini M; Scalise G
    Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):885-9. PubMed ID: 10691200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.
    Asadpour M; Namazi F; Razavi SM; Nazifi S
    Vet Parasitol; 2018 Jan; 250():7-14. PubMed ID: 29329627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an immunocompetent mouse model susceptible to Cryptosporidium tyzzeri infection.
    Huang Y; Song Y; You Y; Mi R; Han X; Gong H; Chen Z; Liu Y
    Parasite Immunol; 2021 Jan; 43(1):e12800. PubMed ID: 33068486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
    Rueda C; Fenoy S; Simón F; Del Aguila C
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have
    Bartelt LA; Bolick DT; Kolling GL; Stebbins E; Huston CD; Guerrant RL; Hoffman PS
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297368
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.
    Mancassola R; Reperant JM; Naciri M; Chartier C
    Antimicrob Agents Chemother; 1995 Jan; 39(1):75-8. PubMed ID: 7695333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.
    Verdon R; Polianski J; Gaudebout C; Marche C; Garry L; Pocidalo JJ
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1681-2. PubMed ID: 7979310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis.
    Dayao DA; Jaskiewcz J; Lee S; Oliveira BC; Sheoran A; Widmer G; Tzipori S
    Infect Immun; 2022 Jul; 90(7):e0012722. PubMed ID: 35735982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment strategies and drugs in development for cryptosporidiosis.
    Chavez MA; White AC
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.